Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B
Objectives: Few studies have investigated serum levels of platelet-derived growth factor (PDGF) in patients with chronic hepatitis B (CHB). The present study aimed to determine whether PDGF-BB could serve as a potential biomarker for the detection of liver fibrosis. Methods: From October 2013 to Aug...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-08-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971216310876 |
id |
doaj-d80098f78f884144928cc36b8f75a2ed |
---|---|
record_format |
Article |
spelling |
doaj-d80098f78f884144928cc36b8f75a2ed2020-11-24T23:57:53ZengElsevierInternational Journal of Infectious Diseases1201-97121878-35112016-08-0149C949910.1016/j.ijid.2016.06.004Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis BJiyuan Zhou0Yongqiong Deng1Linlin Yan2Hong Zhao3Guiqiang Wang4Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, ChinaDepartment of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, ChinaDepartment of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, ChinaDepartment of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, ChinaDepartment of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, ChinaObjectives: Few studies have investigated serum levels of platelet-derived growth factor (PDGF) in patients with chronic hepatitis B (CHB). The present study aimed to determine whether PDGF-BB could serve as a potential biomarker for the detection of liver fibrosis. Methods: From October 2013 to August 2015, 465 patients with CHB were enrolled prospectively in this study. All patients underwent liver biopsy and staging based on the Ishak system. The serum PDGF-BB level was measured quantitatively by ELISA. Results: The serum PDGF-BB level was negatively correlated with fibrosis stage in all patients (p = 0.003, Spearman's rho = −0.16) and was significantly different between fibrosis stages. The areas under the receiver operating characteristics curves (AUROCs) for serum PDGF-BB level and PGT score (a combination of PDGF-BB, gamma-glutamyl transpeptidase, and platelet levels) were 0.667 and 0.831, respectively, for patients with significant fibrosis and normal alanine aminotransferase (ALT) levels. The AUROCs for aspartate aminotransferase-to-platelet ratio (APRI) and fibrosis index based on four factors (FIB-4) were 0.823 and 0.821, respectively. Importantly, a cut-off value of 1.05 and 1.43, respectively, resulted in a sensitivity of 0.95 and 0.52, a specificity of 0.29 and 0.95, a positive predictive value of 0.30 and 0.79, and a negative predictive value of 0.96 and 0.86. The rate of correct diagnosis was up to 88.4% when using cut-offs of 1.05 and 1.43 for the absence or presence of significant fibrosis, respectively. Conclusions: Serum PDGF-BB decreased remarkably as fibrosis progressed, and this could be used as a non-invasive biomarker for the assessment of fibrosis stage in patients with CHB.http://www.sciencedirect.com/science/article/pii/S1201971216310876Chronic hepatitis BPDGF-BBLiver fibrosisDiagnosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jiyuan Zhou Yongqiong Deng Linlin Yan Hong Zhao Guiqiang Wang |
spellingShingle |
Jiyuan Zhou Yongqiong Deng Linlin Yan Hong Zhao Guiqiang Wang Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B International Journal of Infectious Diseases Chronic hepatitis B PDGF-BB Liver fibrosis Diagnosis |
author_facet |
Jiyuan Zhou Yongqiong Deng Linlin Yan Hong Zhao Guiqiang Wang |
author_sort |
Jiyuan Zhou |
title |
Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B |
title_short |
Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B |
title_full |
Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B |
title_fullStr |
Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B |
title_full_unstemmed |
Serum platelet-derived growth factor BB levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis B |
title_sort |
serum platelet-derived growth factor bb levels: a potential biomarker for the assessment of liver fibrosis in patients with chronic hepatitis b |
publisher |
Elsevier |
series |
International Journal of Infectious Diseases |
issn |
1201-9712 1878-3511 |
publishDate |
2016-08-01 |
description |
Objectives: Few studies have investigated serum levels of platelet-derived growth factor (PDGF) in patients with chronic hepatitis B (CHB). The present study aimed to determine whether PDGF-BB could serve as a potential biomarker for the detection of liver fibrosis.
Methods: From October 2013 to August 2015, 465 patients with CHB were enrolled prospectively in this study. All patients underwent liver biopsy and staging based on the Ishak system. The serum PDGF-BB level was measured quantitatively by ELISA.
Results: The serum PDGF-BB level was negatively correlated with fibrosis stage in all patients (p = 0.003, Spearman's rho = −0.16) and was significantly different between fibrosis stages. The areas under the receiver operating characteristics curves (AUROCs) for serum PDGF-BB level and PGT score (a combination of PDGF-BB, gamma-glutamyl transpeptidase, and platelet levels) were 0.667 and 0.831, respectively, for patients with significant fibrosis and normal alanine aminotransferase (ALT) levels. The AUROCs for aspartate aminotransferase-to-platelet ratio (APRI) and fibrosis index based on four factors (FIB-4) were 0.823 and 0.821, respectively. Importantly, a cut-off value of 1.05 and 1.43, respectively, resulted in a sensitivity of 0.95 and 0.52, a specificity of 0.29 and 0.95, a positive predictive value of 0.30 and 0.79, and a negative predictive value of 0.96 and 0.86. The rate of correct diagnosis was up to 88.4% when using cut-offs of 1.05 and 1.43 for the absence or presence of significant fibrosis, respectively.
Conclusions: Serum PDGF-BB decreased remarkably as fibrosis progressed, and this could be used as a non-invasive biomarker for the assessment of fibrosis stage in patients with CHB. |
topic |
Chronic hepatitis B PDGF-BB Liver fibrosis Diagnosis |
url |
http://www.sciencedirect.com/science/article/pii/S1201971216310876 |
work_keys_str_mv |
AT jiyuanzhou serumplateletderivedgrowthfactorbblevelsapotentialbiomarkerfortheassessmentofliverfibrosisinpatientswithchronichepatitisb AT yongqiongdeng serumplateletderivedgrowthfactorbblevelsapotentialbiomarkerfortheassessmentofliverfibrosisinpatientswithchronichepatitisb AT linlinyan serumplateletderivedgrowthfactorbblevelsapotentialbiomarkerfortheassessmentofliverfibrosisinpatientswithchronichepatitisb AT hongzhao serumplateletderivedgrowthfactorbblevelsapotentialbiomarkerfortheassessmentofliverfibrosisinpatientswithchronichepatitisb AT guiqiangwang serumplateletderivedgrowthfactorbblevelsapotentialbiomarkerfortheassessmentofliverfibrosisinpatientswithchronichepatitisb |
_version_ |
1725452938042671104 |